Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers

  • Why depression and aging are linked to increased disease risk

  • Birth season affects your mood in later life, new research suggests

  • Highly Connected CEOs More Likely to Broker Mergers and Acquisitions That Harm Firms

  • Irritable bowel syndrome: Males report more social stress than females

  • New test to help brain injury victims recover

  • Panic attacks associated with fear of bright daylight

  • Fish intake associated with boost to antidepressant response

  • Aspirin shown to benefit schizophrenia treatment

  • American Alzheimer's plan milestones must be strengthened to meet goal by 2025, experts say

  •